Anti-Abatacept Antibodies
-
Bioanalytical Antibodies
-
Anti-idiotypic Antibodies
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Anti-idiotypic Antibodies
s
s
s
Antibodies for bioanalysis and drug monitoring of abatacept and biosimilars
Develop highly selective and sensitive PK and ADA assays for abatacept (Orencia) using our range of ready-made antibodies.
- Recombinant antibodies specific to abatacept CTLA-4 domain
- Fully human format for surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Stringent quality control for batch to batch consistency
- Tested for use with mouse anti-human CTLA-4 (CD152) antibody
Table 1. Antibodies Specific to Abatacept and CTLA-4.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Abatacept (CTLA-4 domain) Inhibitory |
HCA335 |
AbD37058ia |
Human IgG1 |
1 |
PK bridging ELISA (detection) |
|
|
HCA336 |
AbD37065ia |
Human IgG1 |
6 |
ADA control |
||
|
CTLA-4, (CD152) |
MCA1724 |
BNI3 |
Mouse IgG2a |
n.d. |
PK bridging ELISA (capture) |
* Affinity measured in the monovalent Fab format; not determined for MCA1724.
Anti-Abatacept Inhibitory Antibodies
Abatacept is a recombinant, fusion protein drug consisting of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), linked to a modified Fc portion of human immunoglobulin G1 (hIgG1). Our anti-abatacept antibodies inhibit the binding of the drug to its target CD80. Human Anti-Abatacept Antibody, clone AbD37058ia (HCA335), can be used for detection in a pharmacokinetic (PK) bridging ELISA to measure free drug, paired with Mouse Anti-Human CTLA-4 (CD152) Antibody (MCA1724) as capture reagent. They are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Abatacept PK bridging ELISA using antibodies MCA1724 and HCA335.
Schematic image of PK bridging ELISA measuring free drug. Monoclonal capture antibody, Ig format (gray), fusion protein drug (gold-green), anti-drug detection antibody, Ig format (blue), labeled with HRP.
ADA Bridging ELISA
Fig. 2. Abatacept ADA bridging ELISA using antibody HCA335, HCA336, or MCA1724.
Schematic image of ADA bridging assay. Fusion protein drug as capture and detection reagent labeled with HRP (gold-green), monoclonal anti-drug antibody, Ig format (blue).
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.